Advertisement|Remove ads.

Advertisement|Remove ads.
The SEC’s Division of Corporation Finance said on Tuesday it will not recommend enforcement action if Tesla runs a voluntary program that lets retail shareholders give a standing instruction: vote my shares the way the Tesla board recommends, unless I say otherwise.
Tesla had asked whether a standing, reusable voting choice would break proxy rules that limit early vote-gathering and how long a voting authorization can last. Staff said it would not recommend a case — if Tesla runs the Issuer Voluntary Retail Voting Program exactly as described. The same answer applies to any company that operates the program the same way.
Shareholders would opt in once, for free, through Tesla, a broker, or a shared “hub.” They could follow the board on every item, or on everything except contested director elections and any acquisition, merger, or divestiture that needs a shareholder vote under state law or exchange rules.
Advertisement|Remove ads.
They would still get full proxy materials. They could override any proposal, or cancel the standing instruction, at no cost. Tesla would send at least yearly reminders — plus extra notice before special deals — and disclose the program on its website and in proxy statements. Enrollment would apply starting with the next meeting whose proxy materials had not yet been filed.
Most small holders never vote. Tesla cited Broadridge data that retail investors voted 28% of their shares in the 2025 season, versus 76.6% for institutions. Tesla said a default people can always change could raise turnout without locking anyone in.
Robinhood CEO Vlad Tenev posted that the letter was “clearing the way for a voting program that empowers retail investors” and that Robinhood is “proud to work with the outstanding team at Tesla.” Tesla counsel Brandon Ehrhart posted that retail investors “should be heard.”
Advertisement|Remove ads.
On Stocktwits, retail sentiment around TSLA stock fell from ‘bullish’ to ‘neutral’ over the past 24 hours, while message volume stayed at ‘low’ levels
TSLA stock has fallen 21% year-to-date.
Read More: Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’
Advertisement|Remove ads.
For updates and corrections, email newsroom[at]stocktwits[dot]com
Comments posted here will also appear on symbol pages.